OncoMatch

OncoMatch/Clinical Trials/NCT04166006

A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.

Is NCT04166006 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Autologous DC vaccine and Interleukin-2 for head neck tumors.

Phase 2RecruitingIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSNCT04166006Data as of May 2026

Treatment: Autologous DC vaccine · Interleukin-2Single-arm, monocentric trial to assess safety and immunological efficacy of adjuvant vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV rare cancers (In Head/Neck tumors (H\&N), NEuroendocrine Tumors (NET) and Soft Tissue Sarcomas (STS).

Check if I qualify

Extracted eligibility criteria

Cancer type

Neuroendocrine Tumor

Sarcoma

Disease stage

Required: Stage IV

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Must have received: surgery — radical intent

surgically treated with radical intent

Lab requirements

Blood counts

Haemoglobin >10 g/dl; WBC ≥3000/μl; ANC ≥1500/μl; platelets ≥75000/μl

Kidney function

serum creatinine <1.5x upper institutional reference level

Liver function

AST and ALT <3x upper institutional reference level; total bilirubin <1.5x upper institutional reference level

Cardiac function

Patients aged 70 years or older must have left ventricular ejection fraction not lower than 55% as assessed by echocardiography

Haemoglobin >10 g/dl; White blood cells ≥3000/μl; Absolute neutrophil count ≥1500/μl; Platelets≥75000/μl; AST and ALT <3x upper institutional reference level; Total bilirubin <1.5x upper institutional reference level; Serum creatinine <1.5x upper institutional reference level. Patients aged 70 years or older must have left ventricular ejection fraction not lower than 55% as assessed by echocardiography.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify